BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Andrea Ellis sold 30,000 shares of the firm's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $34.05, for a total value of $1,021,500.00. Following the completion of the sale, the director now directly owns 12,000 shares of the company's stock, valued at approximately $408,600. This trade represents a 71.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
BridgeBio Pharma Stock Performance
BBIO opened at $34.07 on Friday. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $39.47. The company's 50 day simple moving average is $34.13 and its 200 day simple moving average is $29.46. The stock has a market capitalization of $6.48 billion, a PE ratio of -11.95 and a beta of 1.08.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million for the quarter, compared to the consensus estimate of $4.04 million. As a group, sell-side analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.
Institutional Investors Weigh In On BridgeBio Pharma
A number of institutional investors have recently added to or reduced their stakes in BBIO. California State Teachers Retirement System lifted its stake in shares of BridgeBio Pharma by 6.8% in the 4th quarter. California State Teachers Retirement System now owns 115,655 shares of the company's stock valued at $3,174,000 after purchasing an additional 7,388 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in BridgeBio Pharma during the fourth quarter valued at approximately $5,076,000. Mackenzie Financial Corp grew its stake in BridgeBio Pharma by 6.6% during the fourth quarter. Mackenzie Financial Corp now owns 9,505 shares of the company's stock worth $261,000 after buying an additional 592 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of BridgeBio Pharma in the fourth quarter worth $109,000. Finally, Frazier Life Sciences Management L.P. increased its position in shares of BridgeBio Pharma by 1.1% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company's stock worth $104,285,000 after acquiring an additional 40,000 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company's stock.
Wall Street Analyst Weigh In
BBIO has been the subject of several recent analyst reports. Scotiabank raised their price objective on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Friday, February 21st. Redburn Atlantic initiated coverage on shares of BridgeBio Pharma in a research report on Monday. They set a "buy" rating and a $50.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating and issued a $95.00 price target on shares of BridgeBio Pharma in a report on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a report on Monday, March 24th. Finally, Evercore ISI upped their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $52.64.
View Our Latest Stock Analysis on BBIO
About BridgeBio Pharma
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
